Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Objective: The introduction of donor-derived free DNA (ddcfDNA) has emerged as an accurate non-invasive biomarker to diagnose rejection, compared to classical ones. Here we evaluate our experience after its implementation in our center as an in-house technique.
Materials And Methods: Single-center cross-sectional study with extraction of cell-free DNA in blood and quantification of the ddcfDNA using the AlloSeqcfDNA assay (CareDx) at the time of performing biopsies 'per protocol' or 'per indication' between December 2020 and December 2023.
Results: 172 graft biopsies were included (59 for protocol and 113 for cause) in 112 kidney transplant recipients. Among the biopsies, 19 borderline rejections, 11 T-cell mediated rejections, and 30 antibody-mediated rejections were identified. The median ddcfDNA in each diagnostic group was: 0.40% (0.23%-0.82%) in borderline, 0.60% (0.23%-1.91%) in cellular, and 1.48% (0.77%-3.4%) in antibody-mediated rejection (P < .001). In the 112 biopsies with no signs of rejection, the median ddcfDNA was 0.33% (0.17%-0.54%) (P < .001). Cases with positive DSAs and rejection showed higher levels of ddcfDNA than positive DSAs without rejection (P = .010), and ddcfDNA levels were significantly associated with microvascular inflammation and C4d positivity. The area under the ROC curves of ddcfDNA to discriminate any type of rejection from the absence of rejection was 0.74 (0.65-0.82) and, excluding borderline rejection from the analysis, 0.80 (0.72-0.89), outperforming other markers of renal function.
Conclusions: Implementing ddcfDNA analysis at our center as a clinical tool has proven valuable for distinguishing biopsy-confirmed acute rejection, particularly antibody-mediated rejection, outperforming classic renal function markers. Its hospital-based implementation supports timely and accurate diagnosis, improving transplant management and prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nefroe.2025.03.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors.
PLoS One
September 2025
Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Background: Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on overall survival. However, the data underpinning these guidelines are mainly from trials of the 1980s/1990s and have not been updated to reflect the significant advancements in diagnostic and therapeutic options that have emerged over the past 40 years. In this trial, the aim is to test whether a liquid biopsy-based detection of (oligo-) metastatic disease at an early pre-symptomatic stage followed by timely treatment can impact overall survival compared to current standard aftercare.
View Article and Find Full Text PDFIntrinsically disordered region of Clr4/Suv39 regulates its enzymatic activity and ensures heterochromatin spreading.
Nucleic Acids Res
September 2025
Division of Chromatin Regulation, National Institute for Basic Biology, Okazaki 444-8585, Japan.
Methylation of histone H3 at lysine 9 (H3K9me), a hallmark of heterochromatin, is catalyzed by Clr4/Suv39. Clr4/Suv39 contains two conserved domains-an N-terminal chromodomain and a C-terminal catalytic domain-connected by an intrinsically disordered region (IDR). Several mechanisms have been proposed to regulate Clr4/Suv39 activity, but how it is regulated under physiological conditions remains largely unknown.
View Article and Find Full Text PDFBackground: Nucleophosmin 1 (NPM1) mutations represent one of the most frequent genetic alterations in acute myeloid leukemia (AML). However, the prognostic significance of concurrent molecular abnormalities and clinical features in NPM1-mutated AML remains to be fully elucidated.
Methods: We retrospectively analyzed 73 adult AML patients with NPM1 mutations.
CRISPR RNP-Mediated Transgene-Free Genome Editing in Plants: Advances, Challenges and Future Directions for Tree Species.
Plant Cell Environ
September 2025
State Key Laboratory of Tree Genetics and Breeding, Co-Innovation Center for Sustainable Forestry in Southern China, Bamboo Research Institute, Key Laboratory of National Forestry and Grassland Administration on Subtropical Forest Biodiversity Conservation, School of Life Sciences, Nanjing Forestry
CRISPR ribonucleoprotein (RNP)-mediated genome editing offers a transgene-free platform for precise genetic modification in diverse herbaceous and tree species, including rice, wheat, apple, poplar, oil palm, rubber tree and grapevine. However, its application in woody plants faces distinct challenges, notably inefficient delivery and regeneration difficulties, particularly in species such as bamboo. While some of these issues also occur in herbaceous plants, they are often significantly more complex in woody species due to factors such as intricate cell wall architecture, widespread recalcitrant genotypes and inherent limitations of current delivery platforms.
View Article and Find Full Text PDFThe lncRNA ELDR suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility.
Blood Adv
September 2025
Institut de Recherches Cliniques de Montreal - IRCM, Montreal, Quebec, Canada.
Acute myeloid leukemia (AML) with rearrangement of the mixed lineage leukemia gene express MLL-AF9 fusion protein, a transcription factor that impairs differentiation and drives expansion of leukemic cells. We report here that the zinc finger protein GFI1 together with the histone methyltransferase LSD1 occupies the promoter and regulates expression of the lncRNA ELDR in the MLL-r AML cell line THP-1. Forced ELDR overexpression enhanced the growth inhibition of an LSD1i/ATRA combination treatment and reduced the capacity of these cells to generate leukemia in xenografts, leading to a longer leukemia-free survival.
View Article and Find Full Text PDF